US SB741 | 2019-2020 | 116th Congress

Status

Spectrum: Bipartisan Bill
Status: Introduced on March 12 2019 - 25% progression, died in committee
Action: 2019-03-12 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Cancer Drug Parity Act of 2019

Sponsors


History

DateChamberAction
2019-03-12SenateRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

Same As/Similar To

HB1730 (Same As) 2019-03-14 - Referred to the Subcommittee on Health.

Subjects


US Congress State Sources


Bill Comments

feedback